Please login to the form below
human growth hormone
This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.
NICE gives Lilly’s Verzenios chance to compete with rivals
Verzenios (abemaciclib) has been recommended in draft guidance by NICE in combination with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or ... This is for another
Latest news
-
FDA takes aim at pharma’s biosimilar-delaying tactics
Insulin action. Gottlieb is also planning to take action on high prices for insulin and other drugs such as human growth hormone which have seen their prices escalate in recent years.
-
CHMP recommends Teva's generic version of Astellas' Advagraf
The committee also recommended that Faslodex could be used in combination with Pfizer’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative ... The combination can also be used
-
Lilly gets early US approval for Ibrance rival abemaciclib
The US FDA has approved the CDK 4/6 inhibitor - which will be sold as Verzenio - as a combination treatment with hormone drug fulvestrant for hormone receptor-positive, human epidermal growth
-
Versartis crashes as VELOCITY trial veers off track
The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... The long-acting human growth hormone (hGH) product had been billed
-
Surging Trulicity takes sting out of Lilly's arthritis setback
New chief executive David Ricks needs the drug and other growth brands to fire on all cylinders to help Lilly ride through the recent disappointment of a surprise FDA rejection for ... receptor-positive (HR+), human epidermal growth factor receptor
FDA takes aim at pharma’s biosimilar-delaying tactics
CHMP recommends Teva's generic version of Astellas' Advagraf
Lilly gets early US approval for Ibrance rival abemaciclib
Versartis crashes as VELOCITY trial veers off track
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Implementing eHealth innovation
Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
-
Pharma deals during December 2014
costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth
Implementing eHealth innovation
Pharma deals during December 2014
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
-
Digital strategist
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
